Background
Method
Study type and design
Study setting
Sampling technique
Data analysis
Results
Elements for a framework to assess impact
Impact | Alternative product | Disease (disability weight) | Susceptibility | Costs | Number of patients affected (% of population) | |||
---|---|---|---|---|---|---|---|---|
primary aspects | secondary aspects | vulnerability | trust in alternative therapy | to patients | to society | |||
Low | - same substance, licenced, on-label | - same regimen, strength, concentration or instruction for use - different excipients or labelling | 0–0.058 | - 19 - 75 years | full trust | full reimbursement | no extra medicines costs and/or personnel costs | < 0.05 |
Medium | - different substance, licenced, on-label - same substance, unlicenced, on-label - different substance, licenced, off-label - different substance, unlicenced, on-label - different substance, unlicenced, off-label | - interchangeable with extra control - different regimen, strength, concentration or instruction for use or storage | 0.058–0.224 | - 2 – 18 years, - pregnant and nursing women - patients with divergent metabolism | moderate trust | additional payment | minor to moderate extra medicines costs and/or personnel costs | 0.05–0.5 |
High | - no or inferior therapy available | - different route of administration | 0.224–1 | - < 2 years - > 75 years - patients depending on social care | no trust | full payment | high extra medicines costs and/or personnel costs | > 0.5 |
Test cases for data saturation in identification of elements
Application of the proposed framework to the learning cases
Learning case | Alternative product | Disease (disability weigth) | Susceptibility | Costs | Number of patients affected (% of population) | |||
---|---|---|---|---|---|---|---|---|
primary aspects | secondary aspects | vulnerability | trust in alternative therapy | to patients | to society | |||
BCG instillation | no equivalent treatment available | different regimen | 0.288 | > 75 years | no trust | fully reimbursed | no extra costs | 0.03 |
doxycycline tablets | different substance licenced on-label | same regiment and use | 0.051 | 19–75 years | full trust | fully reimbursed | extra medicines costs and personnel costs | 0.71 |
epinephrine auto-injector | same substance and licenced | different instruction | 1 | 3–9 years 19–75 years | moderate trust | fully reimbursed | extra personnel costs | 0.35 |
levothyroxine tablets | same substance, licenced, on-label, | interchangeable with extra control | 0.019 | 19–75 years | no trust | additional payment | no extra costs | 2.06 |
penfluridol tablets | no equivalent treatment available | different regimen | 0.558 | depend on social care | no trust | fully reimbursed | extra medicines costs | 0.08 |